{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:40:59Z","timestamp":1793047259423,"version":"4.5.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pharming Group N.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS) is an ultra-rare inborn error of immunity, characterised by immunodeficiency and immune dysregulation. Having only been recognised in 2013, evidence on APDS is limited. We carried out four systematic literature reviews (SLRs) to identify and narratively synthesise evidence on the following for APDS: epidemiology (epidemiology SLR), clinical efficacy\/safety of treatments (clinical SLR), cost-effectiveness and costs\/healthcare (HCRU) associated with (economic SLR) and health-related quality of life (HRQoL) and utility data (HRQoL SLR) from a global perspective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The Cochrane Collaboration and the University of York\u2019s Centre for Reviews and Dissemination (CRD) guidelines were followed. MEDLINE, Embase, the Cochrane Library, University of York CRD, conference proceedings and other grey literature were searched through to May 2023 for all SLRs, except the epidemiology SLR (searched to Nov 2021); economic databases were also searched for the economic and HRQoL SLRs. Eligible records were: primary epidemiology publications (epidemiology SLR), interventional\/observational studies of treatments (clinical SLR), cost\/HCRU studies\/economic evaluations (economic SLR) and HRQoL\/utility studies (HRQoL SLR) in people with APDS. Risk of bias was assessed using the Downs and Black checklist (clinical SLR) and the Drummond checklist (economic SLR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The numbers of unique relevant studies identified were: 0 (epidemiology SLR), 117 (clinical SLR; 87 reported on &lt;5 patients), 2 (economic SLR) and 1 (HRQoL SLR). The clinical SLR reported symptomatic treatments to be only partially effective at controlling APDS manifestations, with variable tolerability. Outcome reporting was heterogeneous and inconsistent, with small sample sizes and patients receiving multiple treatments, limiting interpretation of results. The economic SLR reported a high direct cost of APDS. Additional HRQoL\/utility studies are required to evaluate the clinical and HRQoL burden of APDS and the impact of therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Four methodologically robust SLRs identified limited evidence on epidemiology, clinical outcomes, costs and HRQoL in APDS, reflecting its ultra-rare nature and recent recognition. This suggests a need for more rigorous data evaluating the clinical and economic effectiveness of APDS treatments. Outcome reporting was highly heterogeneous and inconsistent across studies, sample sizes were small and patients often received multiple treatments, limiting interpretation of results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12865-025-00723-6","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T06:54:02Z","timestamp":1752908042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systematic literature reviews to identify epidemiological, clinical, economic and health-related quality of life evidence in activated PI3K\u03b4 syndrome (APDS)"],"prefix":"10.1186","volume":"26","author":[{"given":"Katerina","family":"Vlachopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Tutein Nolthenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Luscombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keval","family":"Haria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Bolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirah","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"723_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","volume":"16","author":"CL Lucas","year":"2016","unstructured":"Lucas CL, Chandra A, Nejentsev S, et al. PI3 K\u03b4 and primary immunodeficiencies. Nat Rev Immunol. 2016;16:702\u201314.","journal-title":"Nat Rev Immunol"},{"key":"723_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","volume":"40","author":"SG Tangye","year":"2020","unstructured":"Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2020;40:24\u201364.","journal-title":"J Clin Immunol"},{"key":"723_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","volume":"342","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Gar\u00e7on F, et al. Phosphoinositide 3-kinase \u0394 gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342:866\u201371.","journal-title":"Science"},{"key":"723_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fimmu.2018.00369","volume":"9","author":"D Michalovich","year":"2018","unstructured":"Michalovich D, Nejentsev S. Activated PI3 kinase Delta syndrome: from genetics to therapy. Front Immunol. 2018;9:369.","journal-title":"Front Immunol"},{"key":"723_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, et al. The PI3 K pathway in human disease. Cell. 2017;170:605\u201335.","journal-title":"Cell"},{"key":"723_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2021.04.010","volume":"72","author":"NN Brodsky","year":"2021","unstructured":"Brodsky NN, Lucas CL. Infections in activated PI3 K delta syndrome (APDS). Curr Opin Immunol. 2021;72:146\u201357.","journal-title":"Curr Opin Immunol"},{"key":"723_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","volume":"139","author":"TI Coulter","year":"2017","unstructured":"Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase \u0394 syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139:597\u2013606.e4.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gendis.2019.09.015","volume":"7","author":"A Singh","year":"2020","unstructured":"Singh A, Joshi V, Jindal AK, et al. An updated review on activated PI3 kinase delta syndrome (APDS). Genes Dis. 2020;7:67\u201374.","journal-title":"Genes Dis"},{"key":"723_CR9","first-page":"2307","volume":"130","author":"VK Rao","year":"2017","unstructured":"Rao VK, Webster S, Dalm VA, et al. Effective \"activated PI3 K\u03b4 syndrome\"\u2013targeted therapy with the PI3 K\u03b4 inhibitor leniolisib. Blood. J Am Soc Hematol. 2017;130:2307\u201316.","journal-title":"J Am Soc Hematol"},{"key":"723_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","volume":"59","author":"M Jamee","year":"2020","unstructured":"Jamee M, Moniri S, Zaki-Dizaji M, et al. Clinical, immunological, and genetic features in patients with activated PI3 K\u03b4 syndrome (APDS): a systematic review. Clin Rev Allergy Immunol. 2020;59:323\u201333.","journal-title":"Clin Rev Allergy Immunol"},{"key":"723_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","volume":"9","author":"ME Maccari","year":"2018","unstructured":"Maccari ME, Abolhassani H, Aghamohammadi A, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase \u0394 syndrome: the European Society for Immunodeficiencies-activated phosphoinositide 3-kinase \u0394 syndrome registry. Front Immunol. 2018;9:543.","journal-title":"Front Immunol"},{"key":"723_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1046\/j.1525-1497.2003.21246.x","volume":"18","author":"JA Linder","year":"2003","unstructured":"Linder JA, Singer DE. Health-related quality of life of adults with upper respiratory tract infections. J Gen Intern Med. 2003;18:802\u20137.","journal-title":"J Gen Intern Med"},{"key":"723_CR13","unstructured":"APDS - Activated PI3 K delta syndrome: international patient organisation for primary immunodeficiencies. 2020. Available at: https:\/\/www.immunodeficiencyuk.org\/wp-content\/uploads\/2022\/02\/IPOPI_APDSyndrome.pdf. (Accessed: June 2025)."},{"key":"723_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13023-024-03215-9","volume":"19","author":"I Hitchcock","year":"2024","unstructured":"Hitchcock I, Skrobanski H, Matter E, et al. A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS). Orphanet J Rare Dis. 2024;19:203.","journal-title":"Orphanet J Rare Dis"},{"key":"723_CR15","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","volume":"9","author":"TI Coulter","year":"2018","unstructured":"Coulter TI, Cant AJ. The treatment of activated PI3 K\u03b4 syndrome. Front Immunol. 2018;9:2043.","journal-title":"Front Immunol"},{"key":"723_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","volume":"138","author":"E Elkaim","year":"2016","unstructured":"Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase \u0394 syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138:210\u20138.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR17","first-page":"69","volume":"12","author":"AJ Cant","year":"2024","unstructured":"Cant AJ, Chandra A, Munro E, et al. PI3 K\u03b4 pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3 K\u03b4 syndrome and beyond. J Allergy Clin Immunology: Pract. 2024;12:69\u201378.","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"723_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","volume":"8","author":"K Hoegenauer","year":"2017","unstructured":"Hoegenauer K, Soldermann N, Z\u00e9cri F, et al. Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3 K delta-selective inhibitors. ACS Med Chem Lett. 2017;8:975\u201380.","journal-title":"ACS Med Chem Lett"},{"key":"723_CR19","doi-asserted-by":"publisher","first-page":"1337436","DOI":"10.3389\/fphar.2024.1337436","volume":"15","author":"SK De","year":"2024","unstructured":"De SK. Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome. Front Pharmacol. 2024;15:1337436.","journal-title":"Front Pharmacol"},{"key":"723_CR20","unstructured":"United States (US). Food and Drug Administration (FDA). Food and Drug Administration (FDA) approves first treatment for activated phosphoinositide 3-kinase delta syndrome.2023. Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-treatment-activated-phosphoinositide-3-kinase-delta-syndrome. (Accessed: June 2025)."},{"key":"723_CR21","unstructured":"United States Securities and Exchange Commission. Form 6-K. 2024. Available at: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1828316\/000182831624000020\/a2024q1pressrelease.htm. (Accessed: June 2025)."},{"key":"723_CR22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao VK, Webster S, \u0160ediv\u00e1 A, et al. A randomized, placebo-controlled phase 3 trial of the PI3 K\u03b4 inhibitor Leniolisib for activated PI3 K\u03b4 syndrome. Blood. 2023;141:971\u201383.","journal-title":"Blood"},{"key":"723_CR23","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). MHRA approves first medicine for rare immune disease APDS. Available at: https:\/\/www.gov.uk\/government\/news\/mhra-approves-first-medicine-for-rare-immune-disease-apds (Accessed: Oct 2024), 2024."},{"key":"723_CR24","unstructured":"National Institute for Health and Care Excellence (NICE). First licensed treatment for ultra-rare immune disorder recommended. Available at: https:\/\/www.nice.org.uk\/news\/articles\/first-licensed-treatment-for-ultra-rare-immune-disorder-recommended (Accessed: Mar 2025), 2025."},{"key":"723_CR25","unstructured":"University of York Centre for Reviews and Dissemination (CRD). Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care. 2008. Available at: https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. (Accessed: June 2025)."},{"key":"723_CR26","unstructured":"Chandler J, Cumpston M, Li T. Cochrane Handbook for Systematic Reviews of Interventions. 2019. Available at: https:\/\/training.cochrane.org\/handbook\/current. (Accessed: June 2025)."},{"key":"723_CR27","unstructured":"National Institute for Health and Care Excellence (NICE). The social care guidance manual. NICE progress and mathods (MGG10). 2016. Available at: https:\/\/www.nice.org.uk\/process\/pmg10\/chapter\/appendix-b-methodology-checklist-systematic-reviews-and-meta-analyses. (Accessed: June 2025)."},{"key":"723_CR28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336\u201341.","journal-title":"Int J Surg"},{"key":"723_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377\u201384.","journal-title":"J Epidemiol Community Health"},{"key":"723_CR30","unstructured":"Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford University Press; 2015."},{"key":"723_CR31","unstructured":"Alonso G, Liberatore D, Bernasconi A et al. Growth hormone insensitivity in a girl with hyper IgM-like syndrome due to mutation in PIK3R1. Hormone Res Paediatr. 2016;86(suppl 2):1-100."},{"key":"723_CR32","first-page":"368","volume":"34","author":"S Anvari","year":"2014","unstructured":"Anvari S, Uzel G, Jara D, et al. Combined primary immunodeficiency caused by gain-of-function mutations in PIK3CD and alternatives for long-term treatment. J Clin Immunol. 2014;34:368.","journal-title":"J Clin Immunol"},{"key":"723_CR33","first-page":"S25","volume":"40","author":"B Ariue","year":"2020","unstructured":"Ariue B. Central nervous system lesions and later liver lesions in a 20-year-old male with PASLI immunodeficiency. J Clin Immunol. 2020;40:S25.","journal-title":"J Clin Immunol"},{"key":"723_CR34","unstructured":"Azri M, Ismail IH. HyperIgM but not? Med J Malaysia 2021;76(suppl 2)."},{"key":"723_CR35","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1097\/MPH.0000000000001328","volume":"41","author":"F Baleydier","year":"2019","unstructured":"Baleydier F, Ranza E, Sch\u00e4ppi M, et al. Activated phosphoinositide 3 kinase delta syndrome (APDS): a primary immunodeficiency mimicking lymphoma. J Pediatr Hematol Oncol. 2019;41:e521\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"key":"723_CR36","first-page":"S34","volume":"37","author":"MF Barp","year":"2017","unstructured":"Barp MF, Silva PA, Silva PF, et al. Activated phosphoinositide 3-kinase syndrome (APDS): a diagnosis to be aware of. J Clin Immunol. 2017;37:S34.","journal-title":"J Clin Immunol"},{"key":"723_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40272-019-00337-7","volume":"21","author":"M Bevacqua","year":"2019","unstructured":"Bevacqua M, Baldo F, Pastore S, et al. Off-label use of sirolimus and everolimus in a pediatric center: a case series and review of the literature. Paediatr Drugs. 2019;21:185\u201393.","journal-title":"Paediatr Drugs"},{"key":"723_CR38","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1097\/MPH.0000000000001003","volume":"40","author":"D Buchbinder","year":"2018","unstructured":"Buchbinder D, Seppanen M, Rao VK, et al. Clinical challenges: identification of patients with novel primary immunodeficiency syndromes. J Pediatr Hematol Oncol. 2018;40:e319.","journal-title":"J Pediatr Hematol Oncol"},{"key":"723_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/MPH.0000000000001487","volume":"42","author":"M Cansever","year":"2020","unstructured":"Cansever M, Zietara N, Chiang SCC, et al. A rare case of activated phosphoinositide 3-kinase delta syndrome (APDS) presenting with hemophagocytosis complicated with hodgkin lymphoma. J Pediatr Hematol Oncol. 2020;42:156\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"key":"723_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clim.2015.12.008","volume":"178","author":"M Chiriaco","year":"2017","unstructured":"Chiriaco M, Brigida I, Ariganello P, et al. The case of an APDS patient: defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment. Clin Immunol. 2017;178:20\u20138.","journal-title":"Clin Immunol"},{"key":"723_CR41","doi-asserted-by":"publisher","first-page":"757229","DOI":"10.3389\/fped.2021.757229","volume":"9","author":"F Conti","year":"2021","unstructured":"Conti F, Catelli A, Cifaldi C, et al. Corrigendum: case report: hodgkin lymphoma and refractory systemic lupus erythematosus unveil activated phosphoinositide 3-kinase-\u03b4 syndrome 2 in an adult patient. Front Pdiatr. 2021;9:757229.","journal-title":"Front Pead"},{"key":"723_CR42","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.1016\/j.clml.2019.07.287","volume":"19","author":"HM Cordero","year":"2019","unstructured":"Cordero HM, Acon C, Enciso L, et al. Primary immunodeficiency-associated lymphoproliferative disorders in adults. Clin Lymphoma Myeloma Leuk. 2019;19:S314\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"723_CR43","unstructured":"Correa-Jimenez O, Diaz-Maldonado A, Marquez-Herrera K et al. A novel mutation in PI3 KD gene in a patient with chronic systemic inflammation and recurrent abscesses. In J Clin Immunol. 2020;40(suppl 1):1-163."},{"key":"723_CR44","doi-asserted-by":"crossref","unstructured":"Costa Carvalho BT, Campinhos FL, Takano OA et al. Clinical spectrum of a Brazilian cohort of activated phosphoinositide 3-kinase delta syndrome type 1, In CIS Annual Meeting on immune deficiency and dysregulation North American, Springer\/Plenum Publishers, 2017;37(2):215.","DOI":"10.1007\/s10875-017-0372-z"},{"key":"723_CR45","doi-asserted-by":"crossref","unstructured":"Craig M, Geng B, Wigby K et al. Activated phosphoinositide 3-kinase delta syndrome associated with nephromegaly, growth hormone deficiency, bronchiectasis: a case report. Allergy Asthma Clin Immunol. 2022;18:15.","DOI":"10.1186\/s13223-022-00655-5"},{"key":"723_CR46","unstructured":"D\u2019Astous-Gauthier K, Chapdelaine H. A 24-year-old male with activated phosphoinositide 3-kinase delta syndrome (APDS) with novel deletion. In J Clin Immunol, 2020;40(suppl 1):S11-S11."},{"key":"723_CR47","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1172\/JCI75746","volume":"124","author":"MC Deau","year":"2014","unstructured":"Deau MC, Heurtier L, Frange P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124:3923\u20138.","journal-title":"J Clin Invest"},{"key":"723_CR48","unstructured":"Dhami J, Butte M. Activated PI3 K-Delta syndrome: a tale of two siblings with variable clinical phenotypes. J Clin Immunol 2022;42(suppl 1)."},{"key":"723_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jdcr.2018.10.026","volume":"5","author":"SL Donaldson","year":"2019","unstructured":"Donaldson SL, Purnell JC, Pavlidakey PG, et al. Epidermodysplasia verruciformis in a young adult with activated PI3 K\u03b4 syndrome. JAAD Case Rep. 2019;5:195\u20137.","journal-title":"JAAD Case Rep"},{"key":"723_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13223-020-00420-6","volume":"16","author":"M Ewertowska","year":"2020","unstructured":"Ewertowska M, Grze\u015bk E, Urba\u0144czyk A, et al. Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys. Allergy Asthma Clin Immunol. 2020;16:22.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"723_CR51","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1097\/MPG.0000000000002552","volume":"71","author":"Y Ezaizi","year":"2020","unstructured":"Ezaizi Y, Manini ML, Absah I. Gastrointestinal mucosal lymphoid hyperplasia: mutation in PIK3CD gene. J Pediatr Gastroenterol Nutr. 2020;71:e46.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"723_CR52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0000000000001393","volume":"64","author":"S Faraci","year":"2017","unstructured":"Faraci S, Scarselli A, Rea F, et al. Intestinal involvement and subsequent development of lymphoma in activated phosphoinositide 3-kinase syndrome case. J Pediatr Gastroenterol Nutr. 2017;64:265.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"723_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/imj.80_13578","volume":"47","author":"M Gold","year":"2017","unstructured":"Gold M, Chan D, Marchand B, et al. P80: intussception: A novel presentation of activated phosphoinositide 3-kinase-\u2206 (PI3 K\u2206) syndrome (APDS). Intern Med J. 2017;47:28\u20139.","journal-title":"Intern Med J"},{"key":"723_CR54","unstructured":"Gontijo JC Jr, Cancado BLB, Dias RG et al. Report of four cases of activated PI3 kinase delta syndrome. In J Clin Immunol. 2017;37:S22-S22."},{"key":"723_CR55","doi-asserted-by":"crossref","unstructured":"Gonzalez-Granado LI, Dominguez Pinilla N, Allende L et al. Disseminated abscesses due to Mycoplasma faucium in a patient with activated PI3 K\u03b4 syndrome type 2. In J Clin Immunol. 2018;6(5):1796-98.e2.","DOI":"10.1016\/j.jaip.2018.02.014"},{"key":"723_CR56","first-page":"327","volume":"36","author":"RK Goyal","year":"2016","unstructured":"Goyal RK, Uzel G, Pittaluga S, et al. PIK3CD immunodeficiency with colitis, pancreatic insufficiency and ascites. J Clin Immunol. 2016;36:327.","journal-title":"J Clin Immunol"},{"key":"723_CR57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0043-104218","volume":"229","author":"F Hauck","year":"2017","unstructured":"Hauck F, Magg T, Krolo A, et al. Variant PIK3R1 hypermorphic mutation and clinical phenotypes in a family with short statures, mild immunodeficiency and lymphoma. Klinische P\u00e4diatrie. 2017;229:113\u20137.","journal-title":"Klinische P\u00e4diatrie"},{"key":"723_CR58","unstructured":"Holsworth A, Hartog N. Disseminated histoplasmosis in a patient with PIK3CD. In J Clin Immunol. 2020;40(suppl 1):S30\u20131."},{"key":"723_CR59","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.3389\/fimmu.2019.02589","volume":"10","author":"Y Hong","year":"2019","unstructured":"Hong Y, Nanthapisal S, Omoyinmi E, et al. Secondary C1q deficiency in activated PI3 K\u03b4 syndrome type 2. Front Immunol. 2019;10:2589.","journal-title":"Front Immunol"},{"key":"723_CR60","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3349\/ymj.2020.61.6.542","volume":"61","author":"JM Kang","year":"2020","unstructured":"Kang JM, Kim SK, Kim D, et al. Successful sirolimus treatment for Korean patients with activated phosphoinositide 3-kinase \u0394 syndrome 1: the first case series in Korea. Yonsei Med J. 2020;61:542\u20136.","journal-title":"Yonsei Med J"},{"key":"723_CR61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fimmu.2019.00077","volume":"10","author":"D Karanovic","year":"2019","unstructured":"Karanovic D, Michelow IC, Hayward AR, et al. Disseminated and congenital toxoplasmosis in a mother and child with activated PI3-kinase \u0394 syndrome type 2 (APDS2): case report and a literature review of Toxoplasma infections in primary immunodeficiencies. Front Immunol. 2019;10:77.","journal-title":"Front Immunol"},{"key":"723_CR62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imj.14047","volume":"49","author":"M Krummenacher","year":"2019","unstructured":"Krummenacher M, Banovic T. Activated PI3-kinase delta syndrome (APDS) and T-cell lymphoma. Intern Med J. 2019;49:41.","journal-title":"Intern Med J"},{"key":"723_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clim.2015.10.008","volume":"162","author":"M Kuhlen","year":"2016","unstructured":"Kuhlen M, H\u00f6nscheid A, Loizou L, et al. De Novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly. Clin Immunol. 2016;162:27\u201330.","journal-title":"Clin Immunol"},{"key":"723_CR64","doi-asserted-by":"publisher","first-page":"152","DOI":"10.24287\/1726-1708-2023-22-1-152-155","volume":"22","author":"ZA Kuzminova","year":"2023","unstructured":"Kuzminova ZA, Fominykh VV, Kotskaya NN, et al. Secondary Fisher-Evans syndrome in a child with activated PI(3)kd syndrome and lymphoma. Russian Pediatr Hematology\/Oncology Immunopathol. 2023;22:152\u20135.","journal-title":"Russian Pediatr Hematology\/Oncology Immunopathol"},{"key":"723_CR65","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s10875-021-01186-1","volume":"42","author":"A Larrauffie","year":"2022","unstructured":"Larrauffie A, Syrykh C, Tavitian S, et al. Activated PI3 kinase delta syndrome revealed by vasculitis and disseminated toxoplasmosis. J Clin Immunol. 2022;42:688\u201390.","journal-title":"J Clin Immunol"},{"key":"723_CR66","doi-asserted-by":"crossref","unstructured":"Li G-M, Liu H-M, Guan W-Z et al. A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: a case report. Medicine 2019;98(18).","DOI":"10.1097\/MD.0000000000015329"},{"key":"723_CR67","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.14309\/01.ajg.0000613180.48811.fe","volume":"114","author":"L Lindoso","year":"2019","unstructured":"Lindoso L, Deboni M, Dorna MB, et al. Activated PI3 K- delta syndrome (APDS): a monogenic cause of VEO-IBD that impacts on treatment. Am J Gastroenterol. 2019;114:S14.","journal-title":"Am J Gastroenterol"},{"key":"723_CR68","first-page":"S16","volume":"42","author":"P Link","year":"2022","unstructured":"Link P, Pitlick M, Joshi A. Activated PI3 kinase delta syndrome leading to severe intestinal nodular lymphoid hyperplasia treated with sirolimus. J Clin Immunol. 2022;42:S16.","journal-title":"J Clin Immunol"},{"key":"723_CR69","first-page":"698","volume":"54","author":"H Liu","year":"2016","unstructured":"Liu H, Tang XL, Liu JR, et al. Clinical and genetic analysis for activated PI3 K-delta syndrome by PIK3CD gene mutation. Chin Zhonghua Er Ke Za Zhi (Chinese J Pediatrics). 2016;54:698\u2013702.","journal-title":"Chin Zhonghua Er Ke Za Zhi (Chinese J Pediatrics)"},{"key":"723_CR70","unstructured":"Lowe D, Verma N, Dziadzio M et al. Clinical and immunological heterogeneity in a family with the E1021K activating mutation in phosphoinositide 3-kinase delta? In J Clin Immunol. 2014;34:S359-60."},{"key":"723_CR71","doi-asserted-by":"publisher","first-page":"670312","DOI":"10.3389\/fimmu.2021.670312","volume":"12","author":"M Lu","year":"2021","unstructured":"Lu M, Gu W, Sheng Y, et al. Case report: activating PIK3CD mutation in patients presenting with granulomatosis with polyangiitis. Front Immunol. 2021;12:670312.","journal-title":"Front Immunol"},{"key":"723_CR72","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1084\/jem.20141759","volume":"211","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Zhang Y, Venida A, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3 K. J Exp Med. 2014;211:2537\u201347.","journal-title":"J Exp Med"},{"key":"723_CR73","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clim.2018.08.007","volume":"197","author":"Y Luo","year":"2018","unstructured":"Luo Y, Xia Y, Wang W, et al. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase \u0394 syndrome. Clin Immunol. 2018;197:60\u20137.","journal-title":"Clin Immunol"},{"key":"723_CR74","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.anai.2019.08.222","volume":"123","author":"DV Manian","year":"2019","unstructured":"Manian DV, Joshi A. M250 alternative treatment for a patient with phosphoinositide-3-kinase delta (PI3 KD) defect annals of allergy. Asthma Immunol. 2019;123:S109\u201310.","journal-title":"Asthma Immunol"},{"key":"723_CR75","first-page":"S26","volume":"37","author":"FP Mariz","year":"2017","unstructured":"Mariz FP, Goudouris E, Silveira H, et al. Hypertrophic osteoarthritis and liver disease in APDS patient\u2013 case report. J Clin Immunol. 2017;37:S26.","journal-title":"J Clin Immunol"},{"key":"723_CR76","doi-asserted-by":"publisher","first-page":"703056","DOI":"10.3389\/fped.2021.703056","volume":"9","author":"A Marzollo","year":"2021","unstructured":"Marzollo A, Bresolin S, Colavito D, et al. Case report: intestinal nodular lymphoid hyperplasia as first manifestation of activated PI3 K\u03b4 syndrome due to a novel PIK3CD variant. Front Pediatr. 2021;9:703056.","journal-title":"Front Pead"},{"key":"723_CR77","first-page":"71","volume":"5","author":"D Mettman","year":"2017","unstructured":"Mettman D, Thiffault I, Dinakar C, et al. Immunodeficiency-Aassociated lymphoid hyperplasia as a cause of intussusception in a case of activated PI3 K-\u03b4 syndrome. Front Pediatr. 2017;5:71","journal-title":"Front Pead"},{"key":"723_CR78","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1182\/blood.V128.22.1347.1347","volume":"128","author":"M Miano","year":"2016","unstructured":"Miano M, Fioredda F, Grossi A, et al. Single-lineage bone marrow failure driven by 2 novel PI3 KCD mutations. Blood. 2016;128:1347.","journal-title":"Blood"},{"key":"723_CR79","unstructured":"Moreira I, Seminario AG, Regairaz L et al. PIK3CD mutation in a patient with common variable immunodeficiency. In J Clin Immunol. 2018;38(3)."},{"key":"723_CR80","doi-asserted-by":"publisher","first-page":"688022","DOI":"10.3389\/fped.2021.688022","volume":"9","author":"N Moreno-Corona","year":"2021","unstructured":"Moreno-Corona N, Chentout L, Poggi L, et al. Two monogenetic disorders, activated PI3-Kinase-\u03b4 syndrome 2 and Smith\u2013Magenis syndrome, in one patient: case report and a literature review of neurodevelopmental impact in primary immunodeficiencies associated with disturbed PI3 K signaling. Front Pediatr. 2021;9:688022.","journal-title":"Front Pead"},{"key":"723_CR81","unstructured":"Ngu ST, French P, Jury C et al. Resolution of primary cutaneous anaplastic large cell lymphoma with Rapamycin. In Br J Dermatol 2017;177:22-22."},{"key":"723_CR82","first-page":"249","volume":"36","author":"P Olbrich","year":"2016","unstructured":"Olbrich P, Sanchez B, Lucena Soto JM, et al. Streptococcus pneumonia adenitis and hyper IgM syndrome in a child with PIK3R1 mutation. J Clin Immunol. 2016b;36:249.","journal-title":"J Clin Immunol"},{"key":"723_CR83","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/pai.12585","volume":"27","author":"P Olbrich","year":"2016","unstructured":"Olbrich P, Lorenz M, Cura Daball P, et al. Activated PI3 K\u03b4 syndrome type 2: two patients, a novel mutation, and review of the literature. Pediatr Allergy Immunol. 2016a;27:640\u20134.","journal-title":"Pediatr Allergy Immunol"},{"key":"723_CR84","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fped.2018.00402","volume":"6","author":"MN Pham","year":"2018","unstructured":"Pham MN, Cunningham-Rundles C. Evaluation of lymphoproliferative disease and increased risk of lymphoma in activated phosphoinositide 3 kinase delta syndrome: A case report with discussion. Front Pediatr. 2018;6:402.","journal-title":"Front Pead"},{"key":"723_CR85","doi-asserted-by":"publisher","first-page":"AB18","DOI":"10.1016\/j.jaci.2016.12.014","volume":"139","author":"D Pourang","year":"2017","unstructured":"Pourang D, Samant SA. Two brothers with immunodeficiency: mixed clinical findings with a common diagnosis. J Allergy Clin Immunol. 2017;139:AB18.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR86","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s10875-020-00843-1","volume":"40","author":"L Ramirez","year":"2020","unstructured":"Ramirez L, Tamayo W, Ale H. APDS2 and SHORT syndrome in a teenager with PIK3R1 pathogenic variant. J Clin Immunol. 2020;40:1020\u20135.","journal-title":"J Clin Immunol"},{"key":"723_CR87","doi-asserted-by":"crossref","unstructured":"Rivalta B, Amodio D, Giancotta C et al. Case report: successful treatment with monoclonal antibodies in one APDS patient with prolonged SARS-CoV-2 infection not responsive to previous lines of treatment. Front Immunol 2022;13:891274.","DOI":"10.3389\/fimmu.2022.891274"},{"key":"723_CR88","doi-asserted-by":"crossref","unstructured":"Rivalta B, Amodio D, Milito C et al. Case report: EBV chronic infection and lymphoproliferation in four APDS patients: the challenge of proper characterization, therapy, and follow-up. Front Pediatr 2021:9:703853.","DOI":"10.3389\/fped.2021.703853"},{"key":"723_CR89","doi-asserted-by":"crossref","unstructured":"Sanchez Clemente N, Penner J, Breuer J et al. Case report: a severe paediatric presentation of COVID-19 in APDS2 immunodeficiency. Front Immunol 2022;13:881259.","DOI":"10.3389\/fimmu.2022.881259"},{"key":"723_CR90","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/MPH.0000000000002214","volume":"43","author":"SA Schworer","year":"2021","unstructured":"Schworer SA, Francis OL, Johnson SM, et al. Autoimmune cytopenia as an early and initial presenting manifestation in activated PI3 kinase delta syndrome: case report and review. J Pediatr Hematol Oncol. 2021;43:281\u20137.","journal-title":"J Pediatr Hematol Oncol"},{"key":"723_CR91","unstructured":"Semeraro M. Sustained clinical improvement in three patients affected by activated phosphoinositide 3-kinase delta syndrome (APDS) treated by the selective PI3 KDelta inhibitor leniolisib. IPIC (CS10). Virtual; 2022."},{"key":"723_CR92","volume-title":"Activated PI3 K-Delta syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model IPIC","author":"I Serra","year":"2022","unstructured":"Serra I. Activated PI3 K\u03b4 syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model IPIC. Portugal: Vilamoura; 2022."},{"key":"723_CR93","doi-asserted-by":"crossref","unstructured":"Serra I, Manusama OR, Kaiser FMP et al. Activated PI3 Kdelta syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model. Brain Behavior Immun Health. 2021;18:100377.","DOI":"10.1016\/j.bbih.2021.100377"},{"key":"723_CR94","unstructured":"Steward C, Wilson K, Ingram W et al. Major amelioration of immune deficiency and autoimmunity by reduced intensity unrelated donor transplantation in siblings with heterozygous gain of function mutations of PIK3CD. Bone Marrow Transplant 2016;1(S291)."},{"key":"723_CR95","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.anai.2017.08.187","volume":"119","author":"A Stoner","year":"2017","unstructured":"Stoner A, Kennedy J, Berlinski A, et al. P271 experience with two patients with activated PI3 K delta syndrome. Ann Allergy Asthma Immunol. 2017;119:S69.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"723_CR96","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00011-021-01479-6","volume":"70","author":"G Su","year":"2021","unstructured":"Su G, Lai J, Zhu J, et al. Analysis of five cases of onogenic lupus related to primary immunodeficiency diseases. Inflamm Res. 2021;70:1211\u20136.","journal-title":"Inflamm Res"},{"key":"723_CR97","first-page":"S460","volume":"1","author":"M Sugiyama","year":"2016","unstructured":"Sugiyama M, Terashita Y, Ohshima J, et al. Successful allogeneic unrelated bone marrow transplantation in a female patient with a heterozygous splice-site mutation in PIK3R1. Bone Marrow Transplant. 2016;1:S460\u20131.","journal-title":"Bone Marrow Transplant"},{"key":"723_CR98","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1093\/rheumatology\/keac436","volume":"62","author":"B Sun","year":"2023","unstructured":"Sun B, Zhou S, Yang H, et al. Tofacitinib as a possible treatment for arthritis in an APDS2 patient. Rheumatology (Oxford). 2023;62:e39\u201341.","journal-title":"Rheumatology (Oxford)"},{"key":"723_CR99","unstructured":"Sundquist B, Rosenzweig S, Pasha M. Primary immunodeficiency due to mutations in PIK3CD: a follow-up of a patient with combined immunodeficiency and lymphoproliferative disease (P171). Ann Allergy Asthma Immunol. 2015."},{"key":"723_CR100","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3389\/fimmu.2019.00753","volume":"10","author":"TJ Thauland","year":"2019","unstructured":"Thauland TJ, Pellerin L, Ohgami RS, et al. Case study: mechanism for increased follicular helper T cell development in activated PI3 K delta syndrome. Front Immunol. 2019;10:753.","journal-title":"Front Immunol"},{"key":"723_CR101","unstructured":"Toribio-Dionicio C, Cubas-Guzman D, Cordova-Calderon W. Activated PI3 K delta syndrome (APDS) in two Peruvian pediatric patients. J Clin Immunol. 2020;40(suppl1):S68-9."},{"key":"723_CR102","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jaci.2016.03.055","volume":"138","author":"Y Tsujita","year":"2016","unstructured":"Tsujita Y, Mitsui-Sekinaka K, Imai K, et al. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase \u0394 syndrome\u2013like immunodeficiency. J Allergy Clin Immunol. 2016;138:1672\u201380.e10.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR103","doi-asserted-by":"publisher","first-page":"108311","DOI":"10.1016\/j.clim.2019.108311","volume":"210","author":"JG Wallace","year":"2020","unstructured":"Wallace JG, Zambrano-Rodas P, C\u00f3rdova-Calder\u00f3n W, et al. Dysregulated actin dynamics in activated PI3 K\u03b4 syndrome. Clin Immunol. 2020;210:108311.","journal-title":"Clin Immunol"},{"key":"723_CR104","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.gendis.2020.04.012","volume":"8","author":"Y Wang","year":"2021","unstructured":"Wang Y, Yang Q, Chen X, et al. Phenotypic characterization of patients with activated PI3 K\u03b4 syndrome 1 presenting with features of systemic lupus erythematosus. Genes Dis. 2021;8:907\u201317.","journal-title":"Genes Dis"},{"key":"723_CR105","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.chest.2018.07.042","volume":"155","author":"M Wentink","year":"2019","unstructured":"Wentink M, Peeters D, van der Burg M, et al. A 3-year-old girl with a mediastinal mass. Chest. 2019;155:e13\u20136.","journal-title":"Chest"},{"key":"723_CR106","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00277-022-04809-8","volume":"101","author":"H Yagasaki","year":"2022","unstructured":"Yagasaki H, Hirai M, Kanezawa K, et al. Successful treatment for diffuse large B-cell lymphoma in a Japanese adolescent with PIK3CD germ-line mutation: stem cell transplantation after reduced-intensity conditioning. Ann Hematol. 2022;101:1617\u20139.","journal-title":"Ann Hematol"},{"key":"723_CR107","first-page":"964","volume":"42","author":"BK Yang","year":"2021","unstructured":"Yang BK, Wu T, An YQ, et al. Activated phosphoinositide 3-kinase delta syndrome: a case report. Chin Zhonghua Xue Ye Xue Za Zhi (Chinese J Hematology). 2021;42:964.","journal-title":"Chin Zhonghua Xue Ye Xue Za Zhi (Chinese J Hematology)"},{"key":"723_CR108","doi-asserted-by":"publisher","first-page":"E32816","DOI":"10.1097\/MD.0000000000032816","volume":"102","author":"X Yang","year":"2023","unstructured":"Yang X, Xi R, Bai J, et al. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase delta syndrome: case report and literature review. Med (Spain). 2023;102:E32816.","journal-title":"Med (Spain)"},{"key":"723_CR109","first-page":"941","volume":"19","author":"R Yazdani","year":"2019","unstructured":"Yazdani R, Hamidi Z, Babaha F, et al. PIK3R1 mutation associated with hyper IgM (APDS2 syndrome): a case report and review of the literature. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune. Endocr Metabolic Disorders). 2019;19:941\u201358.","journal-title":"Endocr Metabolic Disorders)"},{"key":"723_CR110","doi-asserted-by":"crossref","unstructured":"Yin J, Ma J, Xia J et al. Activated PI3 Kdelta syndrome 1 mimicking systemic lupus erythematosus and secondary Sjogren\u2019s syndrome-like phenotype without recurrent infections: a case report. Front Pediatr 2022;10:1077324.","DOI":"10.3389\/fped.2022.1077324"},{"key":"723_CR111","doi-asserted-by":"crossref","unstructured":"Yin Z, Tian X, Zou R et al. Case report: first occurrence of plasmablastic lymphoma in activated phosphoinositide 3-kinase delta syndrome. Front Immunol 2021;12:813261.","DOI":"10.3389\/fimmu.2021.813261"},{"key":"723_CR112","first-page":"673","volume":"33","author":"KJ Zhang","year":"2013","unstructured":"Zhang KJ, Husami A, Marsh R, et al. Identification of a phosphoinositide 3-kinase (PI-3K) p110delta (PIK3CD) deficient individual. J Clin Immunol. 2013;33:673\u20134.","journal-title":"J Clin Immunol"},{"key":"723_CR113","doi-asserted-by":"crossref","unstructured":"Zhang Q, Cui L, Zhao YZ et al. Gain of function mutations of PIK3CD as a cause of chronic active Epstein-Barr virus infection. In Conference: 34th Annual Meeting of the Histiocyte Society, Lisbon, Portugal, Pediatric Blood and Cancer. 2019;66(S1):S53-4.","DOI":"10.1002\/pbc.27548"},{"key":"723_CR114","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ped4.12101","volume":"2","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Ma H, Ma J, et al. Clinical and genetic analysis of immunodeficiency-related diseases associated with PIK3CD mutations. Pediatr Invest. 2018;2:257\u201362.","journal-title":"Pediatr Invest"},{"key":"723_CR115","doi-asserted-by":"publisher","first-page":"300060521101322","DOI":"10.1177\/03000605211013222","volume":"49","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wang J, Zhu K, et al. Activated phosphoinositide 3-kinase delta syndrome misdiagnosed as anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report. J Int Med Res. 2021;49:3000605211013222.","journal-title":"J Int Med Res"},{"key":"723_CR116","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10875-020-00873-9","volume":"41","author":"M Inoue","year":"2021","unstructured":"Inoue M, Isoda T, Yamashita M, et al. Cytomegalovirus laryngitis in primary combined immunodeficiency diseases. J Clin Immunol. 2021;41:243\u20137.","journal-title":"J Clin Immunol"},{"key":"723_CR117","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s10875-021-00966-z","volume":"41","author":"A Nishimura","year":"2021","unstructured":"Nishimura A, Aoki Y, Ishiwata Y, et al. Hematopoietic cell transplantation with reduced intensity conditioning using fludarabine\/busulfan or fludarabine\/melphalan for primary immunodeficiency diseases. J Clin Immunol. 2021;41:944\u201357.","journal-title":"J Clin Immunol"},{"key":"723_CR118","first-page":"413","volume":"58","author":"QY Yang","year":"2020","unstructured":"Yang QY, Jia YJ, Wang YP, et al. Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase \u0394 syndrome 2. Zhonghua Er Ke Za Zhi (Chinese J Pediatrics). 2020;58:413\u20137.","journal-title":"Zhonghua Er Ke Za Zhi (Chinese J Pediatrics)"},{"key":"723_CR119","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1084\/jem.20180010","volume":"215","author":"DT Avery","year":"2018","unstructured":"Avery DT, Kane A, Nguyen T, et al. Germline-activating mutations in PIK3CD compromise B cell development and functionb cell defects due to hyperactive PI3 kinase. J Exp Med. 2018;215:2073\u201395.","journal-title":"J Exp Med"},{"key":"723_CR120","doi-asserted-by":"publisher","first-page":"102201","DOI":"10.1016\/j.pupt.2023.102201","volume":"79","author":"M Begg","year":"2023","unstructured":"Begg M, Amour A, Jarvis E, et al. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of activated PI3 kinase delta syndrome. Pulm Pharmacol Ther. 2023;79:102201.","journal-title":"Pulm Pharmacol Ther"},{"key":"723_CR121","first-page":"706","volume":"9","author":"M Bloomfield","year":"2021","unstructured":"Bloomfield M, Klocperk A, Zachova R, et al. Natural course of activated phosphoinositide 3-kinase delta syndrome in childhood and adolescence. Front Pediatr. 2021;9:706.","journal-title":"Front Pead"},{"key":"723_CR122","first-page":"S44","volume":"37","author":"FL Campinhos","year":"2017","unstructured":"Campinhos FL, Chiabai J, Torgerson TR, et al. Novel mutation causing activated PIK3KINASE delta syndrome (APDS) in a Brazilian family. J Clin Immunol. 2017;37:S44\u201344.","journal-title":"J Clin Immunol"},{"key":"723_CR123","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2020.00239","volume":"11","author":"AY Chan","year":"2020","unstructured":"Chan AY, Leiding JW, Liu X, et al. Hematopoietic cell transplantation in patients with primary immune regulatory disorders (PIRD): a primary immune deficiency treatment consortium (PIDTC) survey. Front Immunol. 2020;11:239.","journal-title":"Front Immunol"},{"key":"723_CR124","doi-asserted-by":"publisher","first-page":"AB235","DOI":"10.1016\/j.jaci.2020.12.005","volume":"147","author":"P Conrey","year":"2021","unstructured":"Conrey P, Sayed S, Espinoza D, et al. Activated PI3 kinase delta syndrome alters CD4 and CD8 T cell activation and is only partially corrected by targeted therapy. J Allergy Clin Immunol. 2021;147:AB235.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR125","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.4049\/jimmunol.2000326","volume":"205","author":"N Diaz","year":"2020","unstructured":"Diaz N, Juarez M, Cancrini C, et al. Seletalisib for activated PI3 Kdelta syndromes: Open-label phase 1b and extension studies. J Immunol. 2020;205:2979\u201387.","journal-title":"J Immunol"},{"key":"723_CR126","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.bbmt.2019.12.079","volume":"26","author":"D Dimitrova","year":"2020","unstructured":"Dimitrova D, Nademi Z, Maccari ME, et al. International retrospective study of allogeneic hematopoietic cell transplantation (HCT) for activated phosphoinositide 3-kinase delta (PI3 K) syndrome. Biol Blood Marrow Transplant. 2020;26:S14\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"key":"723_CR127","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cei.12706","volume":"183","author":"M Elgizouli","year":"2016","unstructured":"Elgizouli M, Lowe DM, Speckmann C, et al. Activating PI3 K\u03b4 mutations in a cohort of 669 patients with primary immunodeficiency. Clin Experimental Immunol. 2016;183:221\u20139.","journal-title":"Clin Experimental Immunol"},{"key":"723_CR128","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/08820139.2020.1863982","volume":"51","author":"S Fekrvand","year":"2021","unstructured":"Fekrvand S, Delavari S, Chavoshzadeh Z, et al. The first Iranian cohort of pediatric patients with activated phosphoinositide 3-kinase-\u03b4 (PI3 K\u03b4) syndrome (APDS). Immunol Investig. 2021;51:644\u201359.","journal-title":"Immunol Investig"},{"key":"723_CR129","first-page":"917","volume":"131","author":"TA Fox","year":"2018","unstructured":"Fox TA, Chakraverty R, Burns S, et al. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood J Am Soc Hematol. 2018;131:917\u201331.","journal-title":"Blood J Am Soc Hematol"},{"key":"723_CR130","first-page":"S286","volume":"34","author":"K Imai","year":"2014","unstructured":"Imai K, Tsujita Y, Mitsui-Sekinaka K, et al. Hematopoietic stem cell transplantation for the patients with activated PI3 K-delta syndrome. J Clin Immunol. 2014;34:S286\u20137.","journal-title":"J Clin Immunol"},{"key":"723_CR131","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4049\/jimmunol.192.Supp.53.7","volume":"192","author":"C Lucas","year":"2014","unstructured":"Lucas C, Lenardo M. Activating mutations in p110delta cause human immunodeficiency and reveal important roles of PI3 K in T cell senescence and homeostatic cell death. J Immunol. 2014;192:53:7.","journal-title":"J Immunol"},{"key":"723_CR132","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","volume":"15","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15:88\u201397.","journal-title":"Nat Immunol"},{"key":"723_CR133","first-page":"S362","volume":"34","author":"B Martinez","year":"2014","unstructured":"Martinez B, Holland SM, Uzel G. Going with the flow: detection of PI3 K activation in germline PIK3CD mutants. J Clin Immunol. 2014;34:S362\u20133.","journal-title":"J Clin Immunol"},{"key":"723_CR134","first-page":"396","volume":"55","author":"Z Nademi","year":"2020","unstructured":"Nademi Z, Rao K, Lum SH, et al. UK experience in allogeneic hematopoietic stem cell transplantation (HSCT) for activating PI3 K mutations. Bone Marrow Transplant. 2020;55:396\u2013396.","journal-title":"Bone Marrow Transplant"},{"key":"723_CR135","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2018.04.032","volume":"143","author":"T Okano","year":"2019","unstructured":"Okano T, Imai K, Tsujita Y, et al. Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase \u0394 syndrome type 1. J Allergy Clin Immunol. 2019;143:266\u201375.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR136","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10875-022-01218-4","volume":"42","author":"L Qiu","year":"2022","unstructured":"Qiu L, Wang Y, Tang W, et al. Activated phosphoinositide 3-kinase delta syndrome: a large pediatric cohort from a single center in China. J Clin Immunol. 2022;42:837\u201350.","journal-title":"J Clin Immunol"},{"key":"723_CR137","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1182\/blood-2018-99-113426","volume":"132","author":"VK Rao","year":"2018","unstructured":"Rao VK, Webster S, Dalm VA, et al. Safety and efficacy of long term suppression of PI3 Kinase pathway by small molecule PI3 K-Delta inhibitor, leniolisib in APDS (Activated PI3 K\u03b4 Syndrome). Blood. 2018;132:3706","journal-title":"Blood"},{"key":"723_CR138","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/all.15615","volume":"78","author":"VK Rao","year":"2023","unstructured":"Rao VK, Webster S, Sediva A, et al. Immunological and exploratory outcomes from a phase 3, placebo-controlled, randomized clinical trial of PI3 K delta inhibitor leniolisib in patients with activated PI3 K delta syndrome (APDS\/PASLI). Eur J Allergy Clin Immunol. 2023;78:39\u201355.","journal-title":"Eur J Allergy Clin Immunol"},{"key":"723_CR139","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood-2022-160334","volume":"140","author":"VK Rao","year":"2022","unstructured":"Rao VK, Webster S, Sediva A, et al. Interim analysis of safety and hematological parameters of an ongoing long-term open-label extension study of investigational PI3 K\u03b4 inhibitor leniolisib for patients with activated PI3 K delta syndrome (APDS) through December 2021. Blood. 2022;140:1643\u20135.","journal-title":"Blood"},{"key":"723_CR140","first-page":"S1","volume":"42","author":"VK Rao","year":"2022","unstructured":"Rao VK, Webster S, Sediva A, et al. Phase 3 placebo-controlled, randomized clinical trial outcomes of PI3 K delta inhibitor leniolisib in patients with activated PI3 K delta syndrome (APDS\/PASLI). J Clin Immunol. 2022;42:S1\u2013115.","journal-title":"J Clin Immunol"},{"key":"723_CR141","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jaci.2017.11.042","volume":"142","author":"R Ruiz-Garc\u00eda","year":"2018","unstructured":"Ruiz-Garc\u00eda R, Vargas-Hern\u00e1ndez A, Chinn IK, et al. Mutations in PI3 K110\u03b4 cause impaired natural killer cell function partially rescued by rapamycin treatment. J Allergy Clin Immunol. 2018;142:605\u201317.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR142","first-page":"S4","volume":"37","author":"R Ruiz-Garcia","year":"2017","unstructured":"Ruiz-Garcia R, Vargas-Hernandez A, Chinn IK, et al. Mutations in PI3 K110D cause impaired NK cell function partially rescued by rapamycin treatment. J Clin Immunol. 2017;37:S4.","journal-title":"J Clin Immunol"},{"key":"723_CR143","first-page":"S102","volume":"41","author":"G Tessarin","year":"2021","unstructured":"Tessarin G, Baronio M, Rossi S, et al. Activated phosphoinositide 3-kinase delta syndrome 1: clinical and immunological data from an Italian cohort of eight patients. J Clin Immunol. 2021;41:S102\u20133.","journal-title":"J Clin Immunol"},{"key":"723_CR144","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.3390\/jcm9103335","volume":"9","author":"G Tessarin","year":"2020","unstructured":"Tessarin G, Rossi S, Baronio M, et al. Activated phosphoinositide 3-kinase delta syndrome 1: clinical and immunological data from an Italian cohort of patients. J Clin Med. 2020;9:3335.","journal-title":"J Clin Med"},{"key":"723_CR145","first-page":"S164","volume":"34","author":"G Uzel","year":"2014","unstructured":"Uzel G, Stoddard J, Martinez B, et al. A short-term treatment summary using M-TOR inhibitors in patients with germline PIK3CD mutations: prospects for future. J Clin Immunol. 2014;34:S164\u2013164.","journal-title":"J Clin Immunol"},{"key":"723_CR146","doi-asserted-by":"publisher","first-page":"890073","DOI":"10.3389\/fimmu.2022.890073","volume":"13","author":"W Wang","year":"2022","unstructured":"Wang W, Min Q, Lai N, et al. Cellular mechanisms underlying B cell abnormalities in patients with gain-of-function mutations in the PIK3CD gene. Front Immunol. 2022;13:890073.","journal-title":"Front Immunol"},{"key":"723_CR147","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clim.2017.01.004","volume":"176","author":"M Wentink","year":"2017","unstructured":"Wentink M, Dalm V, Lankester AC, et al. Genetic defects in PI3 K\u03b4 affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections. Clin Immunol. 2017;176:77\u201386.","journal-title":"Clin Immunol"},{"key":"723_CR148","first-page":"19","volume":"55","author":"WJ Tang","year":"2017","unstructured":"Tang WJ, Wang W, Luo Y, et al. Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase \u0394 syndrome resulting from PIK3CD mutation. Zhonghua Er Ke Za Zhi (Chinese J Pediatrics). 2017;55:19\u201324.","journal-title":"Zhonghua Er Ke Za Zhi (Chinese J Pediatrics)"},{"key":"723_CR149","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s10875-018-0568-x","volume":"38","author":"Y Wang","year":"2018","unstructured":"Wang Y, Wang W, Liu L, et al. Report of a Chinese cohort with activated phosphoinositide 3-kinase \u0394 syndrome. J Clin Immunol. 2018;38:854\u201363.","journal-title":"J Clin Immunol"},{"key":"723_CR150","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","volume":"149","author":"D Dimitrova","year":"2021","unstructured":"Dimitrova D, Nademi Z, Maccari ME, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3 K-delta syndrome. J Allergy Clin Immunol. 2021;149:410\u201321.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR151","doi-asserted-by":"crossref","unstructured":"Harrington A, Hartog NL, Wu EY et al. Estimated annual costs among patients with activated PI3 K delta syndrome. ISPOR 2023, alue in Health 2023;26(6):S2(EE308).","DOI":"10.1016\/j.jval.2023.03.609"},{"key":"723_CR152","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2023.06.015","volume":"152","author":"ME Maccari","year":"2023","unstructured":"Maccari ME, Wolkewitz M, Schwab C, et al. Activated phosphoinositide 3-kinase \u0394 syndrome: update from the ESID registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol. 2023;152(4):984\u2013e996.e10.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR153","unstructured":"Rao VK, Webster S, Sediva A et al. Immunological and exploratory outcomes from a phase 3, placebo-controlled, randomized clinical trial of PI3 K delta inhibitor leniolisib in patients with activated PI3 K delta syndrome (APDS\/PASLI). 100124. In EAACI Hybrid Congress, Prague, Czech Republic, 2022."},{"key":"723_CR154","first-page":"204","volume":"37","author":"VK Rao","year":"2017","unstructured":"Rao VK, Christ A, Su H, et al. Successful clinical study of leniolisib (CDZ173), a small molecule PI3 K-delta inhibitor, in patients with APDS\/PASLI. J Clin Immunol. 2017;37:204.","journal-title":"J Clin Immunol"},{"key":"723_CR155","doi-asserted-by":"publisher","first-page":"1208567","DOI":"10.3389\/fimmu.2023.1208567","volume":"14","author":"S Vanselow","year":"2023","unstructured":"Vanselow S, Wahn V, Schuetz C. Activated PI3 K\u03b4 syndrome - reviewing challenges in diagnosis and treatment. Front Immunol. 2023;14:1208567.","journal-title":"Front Immunol"},{"key":"723_CR156","unstructured":"Rare Revolution Magazine. An overview of etiological factors, clinical presentation and disease management of activated PI3 K delta syndrome (APDS). 2021. Available at: https:\/\/rarerevolutionmagazine.com\/digitalspotlight\/activated-PI3K-delta-syndrome-apds\/. (Accessed: June 2025)."},{"key":"723_CR157","unstructured":"Rao VK, \u0160ediv\u00e1 A, Dalm V et al. Results of a second interim analysis of an ongoing single-arm open-label extension study of leniolisib in activated PI3 K\u03b4 syndrome: long-term efficacy and safety through to March 2023. In International Primary Immunodeficiencies Congress Rotterdam, 2023."},{"key":"723_CR158","unstructured":"Rao VK, \u0160ediv\u00e1 A, Bloomfield M et al. Assessing long-term treatment with leniolisib and its effects on bronchiectasis in patients with activated PI3 K\u03b4 syndrome (APDS). International Primary Immunodeficiencies Congress, Rotterdam, 2023."},{"key":"723_CR159","unstructured":"Rao VK, Kulm E, Kleiner G et al. Gastrointestinal anifestations in patients with activated PI3 K\u03b4 syndrome (APDS) treated with leniolisib, In International Primary Immunodeficiencies Congress Rotterdam, 2023."},{"key":"723_CR160","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","volume":"153","author":"VK Rao","year":"2024","unstructured":"Rao VK, Kulm E, \u0160ediv\u00e1 A, et al. Interim analysis: open-label extension study of leniolisib for patients with APDS. J Allergy Clin Immunol. 2024;153:265\u201374.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"723_CR161","unstructured":"Tessarin G, Lougaris V, Plebani A et al. Treatment with the selective PI3 K\u03b4 inhibitor leniolisib in an atypical case of activated PI3 K\u03b4 syndrome (APDS), In International Primary Immunodeficiencies Congress, Rotterdam, 2023."},{"key":"723_CR162","unstructured":"Rao VK, \u0160ediv\u00e1 A, Dalm V et al. Randomised, placebo-controlled, phase III trial of leniolisib in activated PI3 KD syndrome: adult versus adolescent subgroup analysis, In International Primary Immunodeficiencies Congress, Rotterdam, 2023."},{"key":"723_CR163","doi-asserted-by":"publisher","first-page":"109524","DOI":"10.1016\/j.clim.2023.109524","volume":"250","author":"A Harrington","year":"2023","unstructured":"Harrington A, Lalibert\u00e9 F, Germain G, et al. Healthcare resource utilization among patients with activated PI3 K\u03b4 syndrome in the United States: a real-world assessment by patient age. Clin Immunol. 2023;250:109524.","journal-title":"Clin Immunol"},{"key":"723_CR164","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10238-023-01259-y","volume":"24","author":"J Hanson","year":"2024","unstructured":"Hanson J, Bonnen PE. Systematic review of mortality and survival rates for APDS. Clin Experimental Med. 2024;24:17.","journal-title":"Clin Experimental Med"},{"key":"723_CR165","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.anai.2023.08.190","volume":"131","author":"A Harrington","year":"2023","unstructured":"Harrington A, Mahendran M, Ramasubramanian R, et al. Overall survival (OS) among patients with activated phosphoinositide-3-kinase delta syndrome (APDS). Annals of allergy. Asthma Immunol. 2023;131:S63\u20134.","journal-title":"Asthma Immunol"},{"key":"723_CR166","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1182\/bloodadvances.2023011000","volume":"8","author":"VK Rao","year":"2024","unstructured":"Rao VK, Kulm E, Grossman J, et al. Long-term treatment with selective PI3 K\u03b4 inhibitor leniolisib in adults with activated PI3 K\u03b4 syndrome. Blood Adv. 2024;8:3092\u2013108.","journal-title":"Blood Adv"},{"key":"723_CR167","unstructured":"Harrington A, Whalen J, Munro E et al. Evaluating the impact of leniolisib treatment on symptoms and health-related quality of life (HRQoL) in activated PI3 K\u03b4 syndrome (APDS). TPS44 - Immune deficiencies and autoimmunity 3. In EAACI Congress, Valencia, Spain, 2024."},{"key":"723_CR168","unstructured":"Higgins JPT, Thomas J, Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5, 2024. Available at: https:\/\/training.cochrane.org\/handbook\/current. (Accessed: June 2025)."}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00723-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-025-00723-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00723-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:36:19Z","timestamp":1757262979000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-025-00723-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":168,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1186\/s12865-025-00723-6","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KV, JTN, JL: Employees of Pharming Group N.V.; JR: Employee of MAP Patient Access, which received payment from Pharming Group N.V. for analytical services for this study; KH, FB, SB: Employees of Costello Medical, which received payment from Pharming Group N.V. for analytical services for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}